PepGen Email Format
Biotechnology ResearchMassachusetts, United States51-200 Employees
PepGen is a mid-sized biotechnology company based in Boston, Massachusetts. It operates in biotechnology research and is developing disease-modifying therapies for serious genetic neuromuscular and neurological disorders, with an emphasis on addressing root causes of these conditions. The company uses an internally developed Enhanced Delivery Oligonucleotide platform to advance its pipeline of potential treatments. Its target customers are patients affected by severe neuromuscular and neurological diseases and the clinicians who treat them. As a clinical-stage company, PepGen pursues oligonucleotide therapies and has shared clinical data from its PGN-EDODM1 program at the IDMC-15 conference in Saguenay, Quebec, in May 2026.